


The Pharmaceutical Industry Response to the Pandemic

Phyllis Arthur
Vice President, Infectious Disease and
Diagnostics Policy
Biotechnology Innovation Organization (BIO)

PACCARB Virtual Public Meeting
September 10, 2020

Covid-19 Pipeline Update

> 700 drugs and vaccines in 7 months




Drug	Active	Inactive	Failed
Antivirals	190	12	5
Treatments	328	7	4
Vaccine	179	0	0
Total	697	19	9

723 initiated, 6 EUA
3.7% attrition so far

Clinical & Preclinical Stage Vaccine Pipeline

 Supported by OWS

 US focused

 Jointly developed



Source: Biomedtracker, Biocentury, BIO Industry Analysis


1. PrEP Biopharm vaccine dsRNA, all others mRNA

Oxford, Astrazeneca: ChAdOx1. Symvivo: bacTRL-Spike. Baylor College: BCG tuberculosis vaccine.

Sinopharm with two vaccines in phase 1 trials (one beginning Apr 12 the other Apr 27)

Info as of August 24, not exhaustive

Vaccines with US Government Funding (OWS)



Lessons learned from the response to COVID-19

- Industry responded quickly to the pandemic and companies worked collaboratively to best leverage technologies, expertise, etc.
- This unprecedented response was made possible in part due to the commitment to public-private partnerships by the USG that does not exist for AMR.
- Investments made before the pandemic, such as those in rapid platform technologies, helped speed industry's ability to respond
- ***How can these lessons be applied to AMR?*** Industry is working together investing in novel solutions by launching the AMR Action Fund


The AMR Action Fund aims to bridge the gap in antibiotic R&D and provide time for necessary policy reforms to re-establish innovation ecosystem

Mission

“

Invest in the clinical development of novel antibiotics to bridge them up to commercialization, providing an opportunity for governments to implement reimbursement reform and pull incentives that re-establish a sustainable market

“



Objectives

Strengthen and accelerate antibiotic R&D to bring 2-4 novel antibiotics to commercialization by end of decade

Catalyze market-based reforms to re-establish a sustainable antibiotic innovation ecosystem

AMR Action Fund to support portfolio assets through VC investments and injection of industry expertise




VC investments

\$1B capital to invest in promising novel antibiotics



"Engaged Owner" fund



Industry expertise

Provide access to industry expertise to accelerate development

...complementing existing initiatives such as CARB-X and Repair-Impact Fund